Skip to main content
Clinical Trials/NCT05859581
NCT05859581RecruitingNot Applicable

To Explore the Value of Colon MRI in Assessing the Status of Retroperitoneal Resection Margin Following Beyond Complete Mesocolic Excision Surgery for Advanced Colon Cancer

Peking University Cancer Hospital & Institute1 site in 1 country29 target enrollmentStarted: April 2, 2023Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
29
Locations
1
Primary Endpoint
Coincidence rate with pathological result

Study Overview

Brief Summary

The goal of this clinical trial is to explore the value of colon MRI in assessing the status of retroperitoneal resection margin (RPRM) for advanced colon cancer.

The main questions it aims to answer are:

  • Concordance between MRI suspected RPRM positive and pathologically confirmed positive.
  • Can RPRM-positive patients undergo beyond complete mesocolic excision (CME) surgery in order to achieve R0 resection?

Participants will undergo colon MRI examination and once MRI suspects RPRM positive, they will receive beyond CME surgery.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Diagnostic
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • primary colon adenocarcinoma confirmed by biopsy
  • preoperative CT suspecting retroperitoneal resection margin (RPRM) positive
  • received colon MRI scan
  • underwent beyond complete mesocolic excision surgery
  • sufficient clinical and pathological results

Exclusion Criteria

  • combined with other malignant tumors
  • simultaneous distant metastasis
  • definite invaded other organs or structures (T4b tumors)

Outcomes

Primary Outcomes

Coincidence rate with pathological result

Time Frame: within 2 weeks after surgery

Coincidence rate between MRI diagnosed retroperitoneal resection margin and pathologically confirmed positive

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Peking University Cancer Hospital & Institute
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials